Lee, J. ., Nair, J. ., Zimmer, A. ., Lipkowitz, S. ., Annunziata, C. ., Merino, M. ., … Kohn, E. . (2018). Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. The Lancet. Oncology. https://doi.org/10.1016/S1470-2045(18)30009-3 (Original work published 2018)